About Autologous Serum

Autologous serum drops are made from a patient’s own blood, processed, diluted, packaged and then returned to that same patient. In this approach platelets are collected from a patient by their clinician or processing pharmacy, centrifuged to remove certain unwanted components resulting in a platelet-enriched-plasma. This is then diluted, packaged in preservative free packaging, frozen and finally dispensed back to the individual patient.

Since platelets used in autologous serum are patient sourced, patients must return to their clinician every 1-3 months to re-donate blood for product “refills.” Serum drops in spite of these and other limitations, have been well documented in the literature for over 30 years as generally safe and effective for dry eye as well as other corneal diseases and conditions. A major reason for their overall positive efficacy in the literature today –  the presence of not one but over 30 nutritive and regenerative components also present in healthy tear film (see below). The fact dry eye is defined as a multifactorial disease caused by not a single (e.g., inflammation) but multiple etiologies, suggests therapies with multiple active ingredients have potential to treat a broader range of dry eye patients vs. today’s single a.i. products.

Sample Articles on Autologous Serum

To learn more about the benefits and limitations of today’s autologous serum, click on the following articles and abstracts: